Clinical Data Disclosure Embraced By Pharma; Now It Needs Partners
Executive Summary
Pfizer has not received many requests for its data and wants to find ways to encourage researchers to make the most use of available data; AstraZeneca’s Gregory Curt says the sharing of trial results eventually could eliminate the need for comparator arms.
You may also be interested in...
ClinicalTrials.gov Still Lacks Many Study Results, JAMA Finds; Do Transparency Efforts Need A Boost?
Industry data transparency initiatives are well-established now, but JAMA study suggests holes in efforts to publicly release clinical trial results.
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.